~365 spots leftby Nov 2028

MOSAIC Mobile Program for Type 2 Diabetes

(MOSAIC Trial)

Recruiting in Palo Alto (17 mi)
+1 other location
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Vanderbilt University Medical Center

Trial Summary

What is the purpose of this trial?

This behavioral clinical trial evaluates an adaptively tailored, mobile phone-delivered intervention (MOSAIC) designed to support adults managing their type 2 diabetes. Adaptive means the intervention can change over time. Tailored means the intervention may be different for different participants. The main questions the study will aim to answer are: 1. Does the diabetes education and support delivered via the MOSAIC adaptive mobile phone-delivered intervention improve outcomes more than diabetes education and support delivered via print materials alone? This aim compares the study arms on outcomes such as glycemic management (hemoglobin A1c), diabetes distress, and psychosocial well-being. This aim also compares the study arms on intervention targets (mediators) including diabetes self-efficacy and self-care behaviors. 2. For whom does the MOSAIC adaptive tailoring approach improve outcomes more than the print materials alone? This aim examines how well the tailoring rules used for the MOSAIC intervention worked for different participants on the outcomes examined in the first aim. Participants will enroll in a 16-month study with assessments every 4 months. Assessments include completion of an A1c test and a survey. For those assigned to MOSAIC, they will experience 12-months of mobile phone-delivered support with 3 opportunities for intervention tailoring.

Research Team

Eligibility Criteria

This trial is for adults with type 2 diabetes who are interested in managing their condition. Participants will be involved in a 16-month study, but specific inclusion and exclusion criteria details are not provided.

Inclusion Criteria

I am 18-75, have type 2 diabetes, take daily medication for it, and own a mobile phone.
My support person is an adult who speaks English and owns a mobile phone.

Exclusion Criteria

Support persons: Demonstrated inability to receive & respond to a text, unable to communicate by phone
I have diabetes but none of the listed conditions or limitations.

Treatment Details

Interventions

  • MOSAIC (Behavioural Intervention)
Trial OverviewThe trial tests an adaptive mobile phone-delivered intervention called MOSAIC against traditional print materials for diabetes education and support. It measures effectiveness by looking at blood sugar control, emotional well-being, self-confidence in managing diabetes, and self-care actions.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MOSAICExperimental Treatment2 Interventions
PWD participants will receive MOSAIC components (monthly phone coaching and text message support for goals and medication adherence) for 12 months. PWD participants will receive high-quality print materials upon enrollment and quarterly newsletters on healthy living with diabetes. All SP participants invited by PWD participants assigned to MOSAIC will receive high-quality print materials upon enrollment and quarterly newsletters on healthy living with diabetes. SPs may participate in monthly phone coaching and/or receive text message support tailored to the goal set by the linked PWD.
Group II: Print MaterialsPlacebo Group1 Intervention
PWD participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on health living with diabetes.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vanderbilt University Medical Center

Lead Sponsor

Trials
922
Recruited
939,000+
Jeffrey R. Balser profile image

Jeffrey R. Balser

Vanderbilt University Medical Center

Chief Executive Officer since 2009

MD and PhD from Vanderbilt University

Rick W. Wright profile image

Rick W. Wright

Vanderbilt University Medical Center

Chief Medical Officer since 2023

MD from University of Missouri-Columbia

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+
Dr. Griffin P. Rodgers profile image

Dr. Griffin P. Rodgers

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Chief Executive Officer since 2007

MD, M.A.C.P.

Dr. Griffin P. Rodgers profile image

Dr. Griffin P. Rodgers

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Chief Medical Officer since 2007

MD, M.A.C.P.

University of Alabama at Birmingham

Collaborator

Trials
1,677
Recruited
2,458,000+
Kierstin Kennedy profile image

Kierstin Kennedy

University of Alabama at Birmingham

Chief Medical Officer since 2022

MD

S. Dawn Bulgarella profile image

S. Dawn Bulgarella

University of Alabama at Birmingham

Chief Executive Officer since 2023

BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham